Updated:
Indalo Therapeutics
Indalo Therapeutics is a St. Louis-based firm with undisclosed leadership and no public investment or operational data.
Indalo Therapeutics
Indalo Therapeutics is a St. Louis-based firm whose corporate purpose and governance are not publicly documented. No founding year or principals are listed in accessible sources. The firm's name suggests a focus on therapeutic drug development, but no pipeline, clinical-stage assets, or approved products have been reported. The absence of a website, LinkedIn presence, or regulatory filings leaves its investment strategy — whether it operates as a venture investor, a drug developer, or a holding company — unconfirmed. There are no known portfolio companies, partnerships, or co-investors associated with the firm. With no team size, AUM, or additional offices reported, Indalo Therapeutics does not appear in institutional databases or news archives. No recent operational events have been identified. Its structural posture — single-entity or fund-based — is unknown. The firm's location in St. Louis places it within a region active in biotech and plant sciences, but no connection to local incubators or academic partners has been established. Without further public disclosure, Indalo Therapeutics remains an unverifiable entity.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
St. Louis
Corporate office
St. Louis, MO, United States
Sector focus
Frequently asked questions
What is Indalo Therapeutics?
Indalo Therapeutics is a firm headquartered in St. Louis, Missouri, that appears focused on therapeutics or biotechnology. However, no public records confirm its business model, stage of development, or whether it operates as an investment vehicle or a drug developer.
Who runs Indalo Therapeutics?
No named principals or leadership team members have been publicly identified for Indalo Therapeutics. The firm does not list management on a website or in any accessible publication as of mid-2026.
How much capital does Indalo Therapeutics manage?
Indalo Therapeutics does not disclose AUM or deployment figures. No regulatory filings or press reports provide a capital estimate.
What investment stages does Indalo Therapeutics target?
Indalo Therapeutics' investment focus has not been documented. It is unclear whether it makes direct investments, fund commitments, or operates as a therapeutic developer.
Which sectors does Indalo Therapeutics focus on?
Based on the firm name, Indalo Therapeutics likely targets therapeutics or biotechnology. No specific sector tags beyond those are confirmed.
Is Indalo Therapeutics a family office?
There is no public information suggesting Indalo Therapeutics is a family office. It is categorized here as an asset manager due to the limited available data.
Where can I find more information about Indalo Therapeutics?
The firm's website is indalotherapeutics.com, but no substantive content was scraped from it as of 2026. It does not have a public LinkedIn profile or appear in major industry databases.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: